Haematologica (Apr 2025)
Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia
- Xiaoshuai Zhang,
- Yunfan Yang,
- Bingcheng Liu,
- Xin Du,
- Xiaodong Wang,
- Huanling Zhu,
- Lu Yu,
- Zongru Li,
- Shasha Zhao,
- Linhua Yang,
- Yanping Ma,
- Li Meng,
- Yanqing Zhang,
- Guohui Li,
- Lijie Yang,
- Baohong Wang,
- Xuehong Ran,
- Jian Huang,
- Na Gao,
- Qin Wen,
- Yan Wen,
- Yuxia Zhao,
- Yu Zhu,
- Yanqiu Han,
- Zhenfang Liu,
- Xin Du,
- Jianyu Weng,
- Robert Peter Gale,
- Li Zhou,
- Yanli Zhang,
- Qian Jiang
Affiliations
- Xiaoshuai Zhang
- Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing
- Yunfan Yang
- Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Sichuan
- Bingcheng Liu
- National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjing
- Xin Du
- Department of Hematology, The Second People’s Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen
- Xiaodong Wang
- Department of Hematology, Sichuan Academy of Medical Sciences Sichuan Provincial People’s Hospital, Sichuan
- Huanling Zhu
- Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Sichuan
- Lu Yu
- Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing
- Zongru Li
- Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing
- Shasha Zhao
- Peking University People’s Hospital, Qingdao
- Linhua Yang
- Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan
- Yanping Ma
- Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan
- Li Meng
- Department of Hematology, Tongji Hospital of Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, Wuhan
- Yanqing Zhang
- Department of Hematology, Shenzhen Hospital of Southern Medical University, Shenzhen
- Guohui Li
- Department of Hematology, Xi’an international medical center hospital, Xi’an
- Lijie Yang
- Department of Hematology, Xi’an international medical center hospital, Xi’an
- Baohong Wang
- Department of Hematology, Weifang People's Hospital, Weifang
- Xuehong Ran
- Department of Hematology, Weifang People's Hospital, Weifang
- Jian Huang
- Department of Hematology, The First Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Zhejiang
- Na Gao
- Department of Hematology, Binzhou Medical University Hospital, Binzhou
- Qin Wen
- Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Chongqing
- Yan Wen
- Department of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming
- Yuxia Zhao
- Department of Hematology, The People's Hospital of Xing'an League, Ulanhot, Inner Mongolia Autonomous Region
- Yu Zhu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing
- Yanqiu Han
- Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia
- Zhenfang Liu
- Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi
- Xin Du
- Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou
- Jianyu Weng
- Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou
- Robert Peter Gale
- Department of Immunology and Inflammation, Centre for Hematology, Imperial College London, London
- Li Zhou
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
- Yanli Zhang
- Department of Hematology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Henan
- Qian Jiang
- Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Peking University People’s Hospital, Qingdao
- DOI
- https://doi.org/10.3324/haematol.2024.287116
- Journal volume & issue
-
Vol. 999,
no. 1
Abstract
Optimizing olverembatinib dose in people with chronic phase chronic myeloid leukemia (CML) is important to increase safety without compromising efficacy. We designed a multi-center retrospective study comparing safety and efficacy of olverembatinib between the recommended dose of 40 mg every other day (QOD; N = 216) and a reduced dose of 30 mg QOD (N = 66) in subjects failing other tyrosine kinase-inhibitors (TKIs). The cohorts were similar in baseline co-variates and adjusted for by propensity score matching (PSM). There were no significant differences in cytogenetic and molecular responses, as well as outcomes between the 2 dose cohorts. However, the proportion of subjects receiving the original olverembatinib dose at the last follow-up was significantly higher in the 30 mg cohort (64% [95%Confidence Interval [CI], 53, 75%] versus 44% [37,51%]; p = 0.004). Also, the proportion of subjects receiving a reduced dose or permanently discontinuing because of adverse event was significantly lower in the 30 mg cohort (21% [9, 33%] versus 41% [34, 48%]; p = 0.003). In summary, olverembatinib, 30 mg QOD starting dose is as effective as a 40 mg starting dose but better tolerated in persons with chronic phase CML failing other TKIs.
